Hemogenyx Pharmaceuticals PLC Presentations at Cancer Immunotherapy Symposia
2020年8月14日 - 3:00PM
RNSニュース (英語)
TIDMHEMO
Hemogenyx Pharmaceuticals PLC
14 August 2020
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the " Company " )
Presentations at Cancer Immunotherapy Symposia
Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce
its participation in this year's Keystone Symposia: Advances in
Cancer Immunotherapy, taking place August 17-19, 2020.
The conference highlights challenges in the long-term efficacy
of current cancer immunotherapies and provides insights into the
mechanistic foundations of and possible solutions to these
problems.
Scientists from the Company will present two posters at this
year's conference, which will be taking place virtually due to the
COVID-19 pandemic. Presentations will be hosted in interactive
ePoster sessions, where scientists from Hemogenyx Pharmaceuticals
will be available to answer questions about their latest
research.
The first poster, entitled "High Affinity FLT3-CD3 Bispecific
Antibody Effectively Eliminates AML in Humanized Mouse Models",
discusses the company's bispecific CDX antibody, designed for the
treatment of acute myeloid leukemia ("AML") and concurrent
conditioning of the bone marrow niche for hematopoietic stem cell
transplantation ("HSCT").
The second poster, entitled "A Novel Anti-FLT3 CAR-T Therapy for
Effective Elimination of AML and Conditioning for Hematopoietic
Stem Cell Transplantation", discusses the Company's newest cell
therapy, chimeric antigen receptor T cells, which express anti-FLT3
antibodies to target and kill AML and condition HSCT.
The Company's bispecific antibody and CAR-T therapies have shown
promising results in both in vitro and in vivo preclinical
experiments and display advantages over current standard of care
treatments for AML due to their increased specificity and efficacy,
underscoring the Company's commitment to breakthrough therapies for
the treatment of blood diseases.
Keystone Symposia on Molecular and Cellular Biology (
https://goo.gl/epxTuf ) is a nonprofit organization with a 48-year
history of convening open, peer-reviewed conferences that connect
the scientific community and accelerate life science discovery. Its
Scientific Advisory Board is comprised of eminent biomedical
scientists whose expertise derives from academia, industry, and the
government ( https://goo.gl/GtwUjT ).
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive headquarters@hemogenyx.com
Officer & Co-Founder
Peter Redmond, Director peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470
0470
Matthew Johnson, Vadim Alexandre,
Soltan Tagiev
Peterhouse Capital Limited Tel: +44 (0)20 7469
0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:
HEMO) headquartered in London, with its wholly-owned US operating
subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York
City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and
complementary product candidates, as well as a platform technology
that it uses as an engine for novel product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. The Company's technology
has the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABIGDISGBDGGX
(END) Dow Jones Newswires
August 14, 2020 02:00 ET (06:00 GMT)
Silver Falcon (LSE:SILF)
過去 株価チャート
から 5 2024 まで 6 2024
Silver Falcon (LSE:SILF)
過去 株価チャート
から 6 2023 まで 6 2024